Francesca Yates

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

Peter Hillmen, Andy C. Rawstron, Kristian Brock et al. · Journal of Clinical Oncology · 2019 · 271 citations · Full text

Medicine, Immunology, Pharmacotherapy +14

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Peter Hillmen, Talha Munir, Andy C. Rawstron et al. · Blood · 2017 · 33 citations

Medicine, Pharmacology, Pharmacotherapy +12

The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease

Niamh Appleby, Toby A. Eyre, Maité Cabes et al. · BMC Cancer · 2019 · 32 citations · Full text

Medicine, Hematology, Oncology +17

Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study

Peter Hillmen, Andy C. Rawstron, Kristian Brock et al. · Blood · 2018 · 31 citations

Medicine, Immunology, Pharmacotherapy +9

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Peter Hillmen, Rebecca H. Boucher, Nichola Webster et al. · Blood · 2020 · 18 citations

Medicine, Oncology, Pharmacotherapy +9